Popular Stories

Recap: Amarin Q2 Earnings

AMRN) rose 2.2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 200.00% over the past year to $0.01, which beat the estimate of ($0.07).

Revenue of $135,317,000 higher by 34.25% from the same period last year, which missed the estimate of $149,480,000.


Earnings guidance hasn’t been issued by the company for now.

Revenue guidance hasn’t been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 04, 2020

View more earnings on AMRN” data-reactid=”25″>View more earnings on AMRN

Time: 07:30 AM

https://www.webcaster4.com/Webcast/Page/2037/35819” data-reactid=”27″>ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2037/35819

Price Action

Company’s 52-week high was at $26.12

Company’s 52-week low was at $3.95

Price action over last quarter: down 5.72%

Company Overview

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa.

View Article Origin Here

Related Articles

Back to top button